Bone Biologics (Bone Biologics) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bone Biologics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bone Biologics's Free Cash Flow for the three months ended in Mar. 2024 was $-1.30 Mil. Bone Biologics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Bone Biologics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Bone Biologics's current FCF Yield % is -526.81%.

The historical rank and industry rank for Bone Biologics's FCF Margin % or its related term are showing as below:

BBLGW's FCF Margin % is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: -7.09
* Ranked among companies with meaningful FCF Margin % only.

Bone Biologics FCF Margin % Historical Data

The historical data trend for Bone Biologics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics FCF Margin % Chart

Bone Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Bone Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Bone Biologics's FCF Margin %

For the Medical Devices subindustry, Bone Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bone Biologics's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bone Biologics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bone Biologics's FCF Margin % falls into.

Bone Biologics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bone Biologics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-9.556	/	0
	=	%

Bone Biologics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.303	/	0
	=	%

Bone Biologics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bone Biologics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bone Biologics (Bone Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLGW) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BBLG:USA

Address

2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803

Website

https://www.bonebiologics.com

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.